ALK and lung carcinoma: In addition, the next-generation ALKI, ceritinib, demonstrated significantly longer PFS and ORR compared to platinum-based chemotherapy in untreated ALK-positive advanced lung cancer patients in the ASCEND-4 trial (median PFS 16.6 vs. 8.1 months, HR = 0.55, p < 0.00001; ORR = 72.5% vs. 26.7%) [15].